Our Focus on Immuno-Oncology
In the field of immuno-oncology, the STAM™ mouse is the most pathologically suitable model for developing new therapeutic drugs for liver cancer.
The utilization of STAM™ mouse enables non-clinical research for the development of liver cancer therapeutics targeting immune cells, tumor microenvironment, and genetic mutations.
NEWS RELEASE
A New Phase in MASH Therapeutics: Resmetirom (THR-β Agonist) and Semaglutide (GLP-1 Receptor Agonist)
In 2024, the U.S. FDA approved Resmetirom (a THR-β agonist) as the first therapeutic agent for MASH. In August…
EVENT
SMC Laboratories to Participate in BIO-Europe 2025 (Austria) Online
SMC Laboratories will be participating digitally in BIO-Europe 2025, one of the largest bio-health conventions…
Stem Cell Res Ther.
MicroRNA-4516 in extracellular vesicles-derived mesenchymal stem cells suppressed integrin αV-mediated lung fibrosis ( doi: 10.1186/s13287-025-04559-0.)
CDAHFD Model
The CDAHFD model is a widely used and well-characterized model for the evaluation of pharmacological efficacy of new treatments against liver inflammation, liver fibrosis and fatty liver diseases such as MASLD (formerly: NAFLD).
